唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松的临床疗效研究  

Efficacy of Zoledronic Acid plus Caltrate Don in the Treatment of Diabetic Osteoporosis

作　　者：韩瑞旸 武子朝 刘少军 王微慎 李涛 曹玮[3] 杜随勇 贾宗海 张惠丽 李润根 

机构地区：[1]兵器工业五二一医院脊柱外科,陕西西安710065 [2]西安市安康医院放射科,陕西西安710000 [3]第四军医大学唐都医院介入放射科,陕西西安710038

出　　处：《现代生物医学进展》2015年第1期104-106,共3页Progress in Modern Biomedicine

基　　金：国家自然科学基金项目(81170400)

摘　　要：目的:观察唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松症的临床疗效。方法:将120例糖尿病性骨质疏松患者随机分为实验组和对照组,实验组60例予唑来膦酸联合钙尔奇D治疗,对照组60例予钙尔奇D治疗。连续治疗12个月后,比较两组患者的骨密度、疼痛评分及不良反应的发生情况。结果:治疗12个月后,实验组患者的股骨颈、股骨粗隆和腰椎正位的骨密度均较对照组明显升高,差异有统计学意义(P<0.05);VAS疼痛评分较对照组显著降低(P<0.05)。治疗过程中,两组均无严重的不良反应发生。结论:唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松临床效果优于钙尔奇D单药治疗。Objective： To investigate the efficacy of Zoledronic acid plus Caltrate D in the treatment of diabetic osteoporosis.Methods： 120 patients diagnosed as diabetic osteoporosis were randomly divided into the experimental group and control group, 60 cases in each group. The control group was treated with Caltrate D and the experimental group was treated with Caltrate D plus Zoledronic acid for 12 months. Then the BMD points of VAS and untoward effect were compared between two groups. Results： After 12 months＇ treatment, the bone mineral density of femoral neck, trochanter, and lumbar spine in the experimental group were significantly higher than those of the control group（P〈0.05）, and the scores of VOA was significantly lower than that of the control group（P〈0.05）. There were no serious adverse reactions during the treatment. Conclusion： Zoledronic acid plus Caltrate D was more effective than Caltrate D alone in the treatment of diabetic osteoporosis.

关 键 词：唑来膦酸 钙尔奇D 糖尿病性骨质疏松 临床疗效 

分 类 号：R587.2[医药卫生—内分泌]